Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0045 in Advanced Solid Tumors
NCT06056323Phase 2Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HB0045 in solid tumor (advanced stage), pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and 1 more, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoints: Dose-Limiting Toxicities up to 21 Days, Maximum Tolerated Dose up to 36 Months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
HB0045
03
Conditions
solid tumor (advanced stage)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)ovarian cancer
Beyond the preview
Go deeper on NCT06056323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056323.